Tech Company Financing Transactions
Gelesis Funding Round
Gelesis closed a $22 million funding round on 3/26/2015. Investors included private investors.
Transaction Overview
Company Name
Announced On
3/26/2015
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will be used to support the continued clinical development of its lead product, Gelesis100, as well as advancing its pipeline product, Gelesis 200, into the clinic. $4 million of the amount includes the conversion of outstanding convertible promissory notes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Boylston St. 1600
Boston, MA 02459
USA
Boston, MA 02459
USA
Phone
Website
Email Address
Overview
Gelesis is transforming obesity and diabetes treatments. Learn how our smart pill (Gelesis100) can safely treat obese and diabetic patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yishai Zohar
Chief Marketing Officer
Harry Leider
Chief Operating Officer
David Pass
Chief Scientific Officer
Elaine Chiquette
Chief Scientific Officer
Alessandro Sannino
Executive Vice President
Hassan Heshmati
VP - Regulatory Affairs
Eyal Ron
Browse more venture capital transactions:
Prev: 3/26/2015: NGM Biopharmaceuticals venture capital transaction
Next: 3/26/2015: HONK Technologies venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs